Skip to content

Feasibility of Laryngeal Mask Airway Gastro on Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Pancreas and Bile Duct Disorders

Is the Gastro LMA a Feasible Alternative to the Use of a Native Airway for Endoscopic Retrograde Cholangiopancreatography (ERCP) Cases?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03775681
Enrollment
33
Registered
2018-12-14
Start date
2019-01-16
Completion date
2020-04-20
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bile Duct Disorder, Endocrine Pancreas Disorder

Brief summary

This trial determines the feasibility of Laryngeal Mask Airway Gastro (Laryngeal Mask Airway) when used on patients who are undergoing endoscopic retrograde cholangiopancreatography for pancreas and bile duct disorders. Laryngeal Mask Airway is a device that helps patients breathe while they are asleep during procedures.

Detailed description

PRIMARY OBJECTIVES: I. To determine the successful completion of endoscopic retrograde cholangiopancreatography (ERCP) with the Laryngeal Mask Airway (LMA) Gastro. SECONDARY OBJECTIVES: I. To determine gastroenterologist satisfaction with the LMA Gastro. II. To determine anesthesia provider satisfaction with the LMA Gastro. III. To determine the rate of unsuccessful LMA Gastro placement. IV. To determine the ability of LMA Gastro to provide adequate oxygenation and ventilation throughout the procedure. V. To determine and describe the rate of adverse events. OUTLINE: Patients wear Laryngeal Mask Airway Gastro after receiving general anesthesia and falling asleep. Patients then undergo standard of care endoscopic retrograde cholangiopancreatography. Patients also complete a 5-minute interview following ERCP procedure.

Interventions

PROCEDUREEndoscopic Retrograde Cholangiopancreatography

Undergo standard of care ERCP

OTHERInterview

Ancillary studies

DEVICELaryngeal Mask Airway

Wear LMA

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients undergoing elective ERCP with general anesthesia

Exclusion criteria

* Patients with propofol allergy * Patients at increased aspiration risk * Patients with abnormal head/neck pathology preventing LMA Gastro placement * Patients with surgical or radiation treatment to the head/neck making LMA Gastro placement difficult * Esophagectomy patients * Patients already intubated upon arrival to endoscopy suite * Patients undergoing endoscopic ultrasound (EUS) * Patients with body mass index (BMI) 35 kg/m\^2 * Non-English speaking patients

Design outcomes

Primary

MeasureTime frameDescription
The Number of Participants With Overall Success of ERCP With LMA GastroUp to 3 monthsSuccessful completion of ERCP with the LMA® Gastro™

Other

MeasureTime frameDescription
Gastroenterologist and Anesthesiologist Satisfaction With the LMA® Gastro™Up to 3 monthsSurveys for gastroenterologist and anesthesiologist satisfaction with the Laryngeal Mask Airway (LMA) Gastro contain items measured on a 10-point Likert scale with 1 reflecting strong disagreement and 10 strong agreement. Mean scores and standard deviations will be used to provide summaries for each survey item. Summaries will be stratified by gastroenterologist and anesthesiologist. Paired differences in survey items between gastroenterologist and anesthesiologist scores will be summarized using descriptive statistics and 95% CIs.

Countries

United States

Participant flow

Recruitment details

Recruitment Period: January 2019 to July 2019

Participants by arm

ArmCount
LMA® Gastro™
Upon anesthesia induction, the LMA® Gastro™ was placed in the patient's oropharynx. The cuff was inflated until the cuff pilot indicator line was within the green zone. Appropriate placement was confirmed with end tidal CO2 and adequate tidal volumes of at least 4-5 cc/kg. The LMA® Gastro™ was secured using the manufacturer provided adjustable holder and strap. A standard sideviewing duodenoscope measuring 11.3mm in maximum diameter was lubricated with KY jelly by the gastroenterologist, coating the full length of the endoscope that was inserted into the LMA® Gastro™.
30
Total30

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision3

Baseline characteristics

CharacteristicLMA® Gastro™
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
15 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
Age, Continuous65 years
Ethnicity (NIH/OMB)
Hispanic or Latino
NA Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
NA Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
NA Participants
Region of Enrollment
United States
30 participants
Sex: Female, Male
Female
12 Participants
Sex: Female, Male
Male
18 Participants
Type of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Diagnostic
3 Participants
Type of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Other
2 Participants
Type of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Stent Exchange
4 Participants
Type of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Stent Placement
12 Participants
Type of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Stent Removal
9 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 30
other
Total, other adverse events
0 / 30
serious
Total, serious adverse events
0 / 30

Outcome results

Primary

The Number of Participants With Overall Success of ERCP With LMA Gastro

Successful completion of ERCP with the LMA® Gastro™

Time frame: Up to 3 months

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA® Gastro™The Number of Participants With Overall Success of ERCP With LMA Gastro28 Participants
Other Pre-specified

Gastroenterologist and Anesthesiologist Satisfaction With the LMA® Gastro™

Surveys for gastroenterologist and anesthesiologist satisfaction with the Laryngeal Mask Airway (LMA) Gastro contain items measured on a 10-point Likert scale with 1 reflecting strong disagreement and 10 strong agreement. Mean scores and standard deviations will be used to provide summaries for each survey item. Summaries will be stratified by gastroenterologist and anesthesiologist. Paired differences in survey items between gastroenterologist and anesthesiologist scores will be summarized using descriptive statistics and 95% CIs.

Time frame: Up to 3 months

ArmMeasureGroupValue (MEAN)
LMA® Gastro™Gastroenterologist and Anesthesiologist Satisfaction With the LMA® Gastro™Discordance3.45 score on a scale
LMA® Gastro™Gastroenterologist and Anesthesiologist Satisfaction With the LMA® Gastro™Concordance96.55 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026